Mpex Pharmaceuticals, Inc.

Melinta Subsidiary Corp.

Horizon Orphan LLC

Rempex Pharmaceuticals, Inc.

Essential Therapeutics, Inc.

Melinta Therapeutics, Inc.

Raptor Pharmaceuticals Inc.

Qpex Biopharma, Inc.

Olga Lomovskaya

David C Griffith

Michael N Dudley

Keith A Bostian

Mark William Surber

Tomasz W Glinka

Scott J Hecker

Gavin C Hirst

Raja K Reddy

Maxim Totrov

Jeffery S Loutit

Elizabeth E Morgan

Serge H Boyer

Dongxu Sun

Jefferey S Loutit

David Mark Wallace

May D Lee

Neil Berkley

Suzanne Chamberland

Jeffrey S Loutit

Karen Fusaro

Serge Henri Boyer

Methods of treating or ameliorating urinary tract infection (UTI), including complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), comprising administering a composition comprising a cyclic boronic acid ester vaborbactam in combination with meropenem are disclosed herewith.

Methods of treating bacterial infections

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising

Use of aerosolized levofloxacin for treating cystic fibrosis

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Aerosolized fluoroquinolones and uses thereof

Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.

Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof

Efflux pump inhibitors are co-administered with antimicrobial agents for the treatment of ophthalmic or otic infections. The agents may be co-administered directly to the site of infection (e.g., the eye or ear).

Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections

This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.

Use and administration of bacterial efflux pump inhibitors

This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. The invention includes novel compounds useful as efflux pump inhibitors, compositions and devices comprising such efflux pump inhibitors, and therapeutic use of such compounds.

Bacterial efflux pump inhibitors and methods of treating bacterial infections

Growing community of inventors

Mill Valley, CA, United States of America

Olga Lomovskaya